Business
Odyssey Group International Announces Upcoming Television Appearance by Brett Favre and Dr. Jake VanLandingham on NewsNation Now’s “The Donlon Report”
Odyssey Group International Announces Upcoming Television Appearance by Brett Favre and Dr. Jake VanLandingham on NewsNation Now’s “The Donlon Report”.
About this update from Odyssey Health Inc.
[{"type":"text","content":"IRVINE, CA / ACCESSWIRE / March 10, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that Dr. Jake VanLandingham, Odyssey's Vice President of Drug Development and the lead scientist developing PRV-002 will be joining Brett Favre to discuss the impact of concussions and the importance of this novel concussion treatment on NewsNation Now's "The Donlon Report." The segment is expected to air at 7:30PM Eastern Time on March 10, 2021."I am pleased that PRV-002, our pre-clinical stage concussion treatment continues to receive so much attention from the media," said Dr. Jake VanLandingham. "We look forward to continuing development of the drug through the initiation of our upcoming human clinical trials."Dr. VanLandingham has appeared alongside Brett Favre on numerous media segments to discuss the impact of concussion and the development of PRV-002 including:CheddarTV's "Closing Bell" on Friday, February 5 (watch online)Newsmax's "National Report" on Sunday, February 7 (watch online) andFox Business' "Kennedy Nation" on Monday February 8 (watch online)In addition, former NFL stars Kurt Warner and Mark Rypien discussed PRV-002 on Fox News' "Fox and Friends" on Saturday, February 6 (watch online).Odyssey acquired PRV-002 via an all-stock transaction that closed March 2, 2021.About Odyssey Group International, Inc.Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.For more information, visit http://www.odysseygi.com.About PRV-002PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concus...